A Survey of the Structures of US FDA Approved Combination Drugs
A Survey of the Structures of US FDA Approved Combination Drugs
复制标题
DOI：
10.1021/acs.jmedchem.8b01610
复制
发表时间：
2019-05-09
影响因子：
7.3
通讯作者：
Njardarson, Jon T.
中科院分区：
文献类型：
--
作者：
Das, Pradipta;Delost, Michael D.;Njardarson, Jon T.
复方药物是美国FDA批准的一类重要药物。自20世纪40年代第一批复方药物获批以来，这些药物一直处于持续增长的轨道上。在这个角度，我们报告了美国FDA批准的组合药物的第一次全面汇编和分析，从1943年首次批准到2018年。我们的数据库包含419种组合药物，由328种独特的小分子结构表示。根据疾病类别、结构、组合成分和批准年份列出了这些药物的分类，以及前24种最常用的小分子组合药物成分。对于经常使用的小分子成分，我们提出了“关系图”，以帮助这些结构的一部分，在许多药物组合的可视化。主体包含10个以疾病为重点的部分，其中显示了用作每个疾病类别组合的一部分的每个小分子组分。
Combination drugs are an important class of US FDA approved pharmaceuticals. These drugs have been on a continuous growth trajectory since the first combination drugs were approved in the 1940s. In this Perspective, we report the first comprehensive compilation and analysis of US FDA approved combination drugs, from the first approval in 1943 through 2018. Our database contains 419 combination drugs, which are represented by 328 unique small molecule structures. Breakdown of these drugs according to disease category, structure, combination composition, and year of approval is presented as well as the top 24 most commonly used small molecule combination drug components. For frequently used small molecule components, we present "relationship diagrams" to aid in the visualization of the many drug combinations these structures are part of. The main body contains 10 disease-focused sections wherein every small molecule component utilized as part of a combination for each disease category is displayed.